Alpha Tau Medical
DRTS | NASDAQ
$11.97
-$1.41 (-10.54%)
At close: Nov 16, 2026, 4:00 PM ET
$12.00
+$0.03 (+0.25%)
After-hours:
Nov 16, 2026, 7:52 PM ET
Alpha Tau Medical Company Profile
Company profile explainedCompany Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Key Executives
| Name | Position |
|---|---|
| Uzi Sofer | Chief Executive Officer & Chairman |
| Raphi Levy | Chief Financial Officer |
| Ronen Segal | Chief Technology Officer |
| Amnon Gat | Chief Operations Officer |
| Rebecca Becker | Vice President of legal |
| Robert Den | Chief Medical Officer & Member of Scientific Advisory Board |
| Yael Zeiger | Corporate Controller |
| Yona Keisari | Chief Scientific Officer |
Alpha Tau Medical
| Country | Israel |
| IPO Date | Mar 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Uzi Sofer |
Contact Details
Kiryat HaMada St. 5 Jerusalem,
JM 9777605 Israel
Stock Details
| Ticker Symbol | DRTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001871321 |
| CUSIP Number | M0740A108 |
| ISIN Number | IL0011839383 |
| SIC Code | 3841 |
Recent News
- 12 hours ago / seekingalpha.comAlpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript
- 16 hours ago / benzinga.comAlpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
- 1 day ago / globenewswire.comAlpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
- 4 days ago / globenewswire.comAlpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
- 19 days ago / globenewswire.comAlpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
- 26 days ago / globenewswire.comAlpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
- 29 days ago / globenewswire.comAlpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
- 1 month ago / globenewswire.comAlpha Tau to Participate in October Investor Conferences
- 2 months ago / seekingalpha.comOramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
- 2 months ago / seekingalpha.comAlpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Add to Watchlist
Select watchlists to add or remove DRTS